Autoantibodies - POTS/ Long Covid / CFS /SFN & other diagnostics

POTS/ Long Covid diagnostics

We offer a test panel for POTS patients. In addition to the tests for CFS diagnostics, this panel also includes testing for anti-muscarinic acetylcholine receptor 1 (M1) antibodies, anti-muscarinic acetylcholine receptor 2 (M2) antibodies, anti-muscarinic acetylcholine receptor 5 (M5) antibodies, as well as testing for alpha-1 adrenergic receptor autoantibodies and alpha-2 adrenergic receptor autoantibodies. Prof. Dr. Kem from the University of Oklahoma Health Sciences Center and VA Medical Center describes for the first time the occurrence of AT1R antibodies in POTS patients. The POTS test profile has therefore been expanded to include AT1R-Ab testing.

Angiotensin II receptor 1 (AT1R) IgG autoantibodies

Endothelin receptor A (ETAR) IgG autoantibodies

Beta-1 adrenergic receptor autoantibodies

Beta-2 adrenergic receptor autoantibody

Muscarinic choline receptor (M1) autoantibody

Muscarinic choline receptor (M2) Auto-antibody

Muscarinic choline receptor (M3) Auto-antibody

Muscarinic choline receptor (M4) Auto-antibody

Muscarinic choline receptor (M5) Autoantibody

Alpha-1 adrenergic receptor Auto-antibody

Alpha-2 adrenergic receptor Auto-antibody

CFS diagnostics

We offer a test system for the diagnosis of chronic fatigue syndrome / myalgic encephalomyelitis (CFS / ME). The results were published in Brain, Behaviour, and Immunity (Löbel M., Scheibenbogen C. et al. 2015 Sep 20).

The tests for the quantitative determination of anti-b1-adrenergic receptor antibodies, anti-b2-adrenergic receptor antibodies, anti-muscarinic acetylcholine receptor 3 (M3) antibodies and anti-muscarinic acetylcholine receptor 4 (M4) antibodies are available too.

Beta-1 adrenergic receptor autoantibody

Beta-2 adrenergic receptor autoantibodies

Muscarinic choline receptor (M3) autoantibody

Muscarinic choline receptor (M4) autoantibody

Small fibre neuropathy (SFN) Diagnostics

Small fibre neuropathy (SFN) is a subtype of neuropathy characterised by selective involvement of unmyelinated or thinly myelinated sensory fibres. Its pathogenesis encompasses a wide range of immune-mediated, metabolic, toxic, hereditary and genetic disorders. SFN has been described in association with Sjögren's syndrome, coeliac disease, systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes mellitus, inflammatory bowel disease, sarcoidosis and paraneoplastic syndrome. Some data also suggest an association with Hashimoto's thyroiditis. Clinical symptoms of SFN can manifest as isolated sensory disturbances as well as isolated autonomic disturbances.

Intravenous immunoglobulin therapy (IVIG) showed a significant effect in the treatment of patients with autoimmune-mediated SFN in two large retrospective studies with comparable response rates (77% and 83% of patients).

Autoantibodies against fibroblast growth factor receptor-3 (FGFR3-IgG) and tri-sulphate heparin di-saccharide (TSHDS-IgM) are elevated in SFN. The efficacy of IVIG administration in FGFR3-Ab and TSHDS-Ab positive patients is currently being investigated in a clinical trial.

FGFR-3 autoantibodies

TSHDS autoantibodies

Other tests (examples - please send us an email to info@apheresiscenter.eu if you are looking for a specific test not listed)

Igm

ANA

Celiac

Mono

EBV

LYME

Herpes

Hormonal panel

Lupus anticoagulant (LA)